Furthermore, incorporating interactions from the STRING database, we found that four genes, TP53, KRAS, ROS1 and BRAF, the known targets of NSCLC drug therapy, were directly or indirectly interconnected with these TFs (Figure 4d). This evidence concerns the gene TP53 and non-small cell lung carcinoma.